Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice

Cancer Chemotherapy and Pharmacology

Volumn 28, Issue 3, 1991, Pages 192-198

  Kawato, Yasuyoshi ^a   Furuta, Tomio ^b   Aonuma, Masashi ^a   Yasuoka, Megumi ^a   Yokokura, Teruo ^b   Matsumoto, Kensuke ^a  

^a DAIICHI SANKYO CO   (Japan)

^b YAKULT CENTRAL INSTITUTE FOR MICROBIOLOGICAL RESEARCH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CAMPTOTHECIN; DOXORUBICIN; FLUOROURACIL; IRINOTECAN; MITOMYCIN C; TEGAFUR;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADENOCARCINOMA; ADMINISTRATION, ORAL; ANIMAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARCINOMA; CARCINOMA, SQUAMOUS CELL; COMPARATIVE STUDY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMAN; INJECTIONS, INTRAVENOUS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; TRANSPLANTATION, HETEROLOGOUS;

EID: 0025785082     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/BF00685508     Document Type: Article

References (24)

1. Topoisomerases as novel targets for cancer chemotherapy
2. Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity
3. Lethal activity of camptothecin sodium on human lymphoma cells
4. A phase II study of a new camptothecin derivative, CPT-11 in previously untreated non-small cell lung cancer (NSCLC)
5. Antitumor activity of CPT-11 against rat Walker 256 carcinoma
6. Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin
7. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts
8. Treatment of malignant melanoma with camptothecin (NSC-100880)
9. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin
10. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I
11. Topoisomerases: novel therapeutic targets in cancer chemotherapy
12. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin
13. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse
14. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors
15. Action of camptothecin on mammalian cells in culture
16. Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice
17. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer
18. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays
19. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies
20. DNA topoisomerases as targets for chemotherapy
21. Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules
22. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo
23. Plant antitumor agents: 1. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata
24. Preclinical evaluation of a new camptothecin derivative, CPT-11, on the subrenal capsule assay